X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
SENS-401 (R-azasetron besylate), is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
SENS-401 (arazasetron), is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
SENS-401 (Arazasetron) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelae hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2022
Details:
SENS-401 (R-azasetron Besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss, aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2022
Details:
SENS-401 demonstrated a statistically significant effect with the high dose on pure tone audiometry (≥ 10 decibels improvement vs placebo) in Phase 2 AUDIBLE-S trial in SSNHL at Day 84 in per protocol idiopathic population (81 patients) treated with corticosteroids.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
SENS-401 (R-azasetron besylate), oral small molecule lead asset currently being investigated in sudden sensorineural hearing loss and cisplatin-induced ototoxicity aims to protect and preserve inner ear tissue from damage.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Association for Research in Otolaryngology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Details:
SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cochlear Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
The poster presented shows SENS-401 ability to yield significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma.
Lead Product(s): R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
